M&A comes back with a bang – or two – in medtech
The preponderance of large deals comes partly as a consequence of soaring market valuations; paradoxically, it is also a cause of them.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.